{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T21:31:24Z","timestamp":1773696684104,"version":"3.50.1"},"reference-count":14,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2009,3,1]],"date-time":"2009-03-01T00:00:00Z","timestamp":1235865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,5]],"date-time":"2019-12-05T00:00:00Z","timestamp":1575504000000},"content-version":"vor","delay-in-days":3931,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2009,3]]},"DOI":"10.1093\/annonc\/mdn758","type":"journal-article","created":{"date-parts":[[2009,1,20]],"date-time":"2009-01-20T01:44:19Z","timestamp":1232415859000},"page":"592-595","source":"Crossref","is-referenced-by-count":44,"title":["The antidiabetic drug metformin: a pharmaceutical AMPK activator to overcome breast cancer resistance to HER2 inhibitors while decreasing risk of cardiomyopathy"],"prefix":"10.1016","volume":"20","author":[{"given":"A.","family":"Vazquez-Martin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Oliveras-Ferraros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"del Barco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Martin-Castillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.A.","family":"Menendez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdn758_bb0010","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/ncponc0509","article-title":"Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer","volume":"3","author":"Nahta","year":"2006","journal-title":"Nat Clin Pract Oncol"},{"key":"10.1093\/annonc\/mdn758_bb0015","doi-asserted-by":"crossref","first-page":"6730","DOI":"10.1158\/1078-0432.CCR-08-0581","article-title":"Acquired resistance to small molecule ErbB2 tyrosine kinase inhibitors","volume":"14","author":"Chen","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdn758_bb0020","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/nrc2106","article-title":"Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition","volume":"7","author":"Force","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"10.1093\/annonc\/mdn758_bb0025","doi-asserted-by":"crossref","first-page":"10607","DOI":"10.1073\/pnas.0701286104","article-title":"Activation of AMP-activated protein kinase by human EGF receptor 2\/EGF receptor tyrosine kinase inhibitor protects cardiac cells","volume":"104","author":"Yarden","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1093\/annonc\/mdn758_bb0030","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.4161\/cc.7.12.6016","article-title":"Activation of AMPK is necessary for killing cancer cells and sparing cardiac cells","volume":"7","author":"Shell","year":"2008","journal-title":"Cell Cycle"},{"key":"10.1093\/annonc\/mdn758_bb0035","doi-asserted-by":"crossref","first-page":"H457","DOI":"10.1152\/ajpheart.00002.2007","article-title":"Metformin and phenformin activate AMP-activated protein kinase in the heart by increasing cytosolic AMP concentration","volume":"293","author":"Zhang","year":"2007","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1093\/annonc\/mdn758_bb0040","doi-asserted-by":"crossref","first-page":"10269","DOI":"10.1158\/0008-5472.CAN-06-1500","article-title":"Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells","volume":"66","author":"Zakikhani","year":"2006","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdn758_bb0045","doi-asserted-by":"crossref","first-page":"10804","DOI":"10.1158\/0008-5472.CAN-07-2310","article-title":"Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells","volume":"67","author":"Dowling","year":"2007","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdn758_bb0050","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1093\/annonc\/mdm589","article-title":"Low-scale phosphoproteome analyses identify the mTOR effector p70 S6 kinase 1 as a specific biomarker of the dual-HER1\/HER2 tyrosine kinase inhibitor lapatinib (Tykerb) in human breast carcinoma cells","volume":"19","author":"Vazquez-Martin","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdn758_bb0055","doi-asserted-by":"crossref","first-page":"11630","DOI":"10.1158\/0008-5472.CAN-07-2401","article-title":"Implication of AMP-activated protein kinase and Akt-regulated survivin in lung cancer chemopreventive activities of deguelin","volume":"67","author":"Jin","year":"2007","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdn758_bb0060","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1158\/0008-5472.CAN-05-2000","article-title":"Regulation of survivin by ErbB2 signaling: therapeutic implications for ErbB2-overexpressing breast cancers","volume":"66","author":"Xia","year":"2006","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdn758_bb0065","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s10517-005-0389-9","article-title":"Metformin decelerates aging and development of mammary tumors in HER-2\/neu transgenic mice","volume":"139","author":"Anisimov","year":"2005","journal-title":"Bull Exp Biol Med"},{"key":"10.1093\/annonc\/mdn758_bb0070","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ccr.2004.06.022","article-title":"PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients","volume":"6","author":"Nagata","year":"2004","journal-title":"Cancer Cell"},{"key":"10.1093\/annonc\/mdn758_bb0075","doi-asserted-by":"crossref","first-page":"5883","DOI":"10.1158\/1078-0432.CCR-06-2837","article-title":"Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency","volume":"13","author":"Lu","year":"2007","journal-title":"Clin Cancer Res"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419414063?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419414063?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/20\/3\/592\/460102\/mdn758.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T13:24:04Z","timestamp":1582205044000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419414063"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3]]},"references-count":14,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,3]]}},"alternative-id":["S0923753419414063"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdn758","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2009,3]]}}}